Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

Rheumatoid arthritis

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

August 6, 2024 Research and Development Levicept, Rheumatology, osteoarthritis, trial

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.
News
Brain picture

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health

August 6, 2024 Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial

Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …
News

National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.

August 6, 2024 Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease

BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …
News
Press release

Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception

August 5, 2024 Research and Development Contraception, UK, contraception, license extension

Gedeon Richter UK Ltd. (“Richter”) today announced that the Medicines Health Regulatory Authority (MHRA) has authorised an extension to the …
News
Press release

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024 Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
News
Press release

Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA for spinal robotics and navigation platform

August 5, 2024 Research and Development 501k clearance, Johnson & Johnson MedTech, Orthopaedics, orthopaedics, robotics, spinal, surgery

Today, the Orthopaedics branch of Johnson & Johnson MedTech, DePuy Synthes, has announced that their surgical robotics system VELYS active …
News

Novo Holdings Invests in Oxford Nanopore Technologies 

August 1, 2024 Research and Development Microbiology, Novo Holdings, Oxford Nanopore Technologies, biopharmacuticals, biotech, data, drug therapies, investment

leading life science investor Novo Holdings, announced a £50m investment in Oxford Nanopore Technologies. Oxford Nanopore Technologies is a leading …
News
handshake

Inizio Engage and Nye Health form a strategic alliance to enhance patient support and outcomes 

August 1, 2024 Research and Development Contraception, Inizio Engage, NHS, Nye Health, alliance, data, patient data, patient experience, support

 Nye Health’s digital platform will be coupled with the patient support experience available at Inizio Engage. The integrated approach will …
News

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024 Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
News
Press release

Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)

July 31, 2024 Research and Development Alzheimers, Conference results, Eisai, Neurology

Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …
News
Press release

Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University

July 31, 2024 Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research

Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …
News

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …
News

AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax

July 30, 2024 Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis

AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI  in combination with MEKTOVI  for the treatment of adult patients with advanced non-small cell lung cancer  NSCLC) with a BRAFV600E mutation

July 29, 2024 Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …
News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024 Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026